Abstract: The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders.

Abstract: The present invention provides improved vaccine compositions having enhanced immunogenicity and methods of using same. The compositions and methods include immunogenic conjugates containing peptide carriers derived from heat shock protein 60 (HSP60). The known synthetic peptide carrier, p458, provides significantly improved immunogenicity when provided as a multimeric conjugate comprising a plurality of peptide carrier units conjugated to each antigen. Cell vaccine compositions comprising antigen presenting cells loaded with multimeric p458 conjugates are also provided.

Abstract: The present invention provides anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising at least one altered phosphorylation site, polynucleotides encoding same and uses thereof. Particularly, the present invention provides variants of human PEDF comprising at least one amino acid substitution at serine residues (24), (114), and (227). The PEDF variants are potent anti-angiogenic factors, and thus useful in treating diseases or disorders associated with neovascularization.

Abstract: The present invention relates to a transgenic plant comprising one or more plant cells transformed with exogenous nucleic acid encoding a Dunaliella salt-inducible or salt-responsive protein selected from the group consisting of elongation initiation factor 3 (eIF3), NADPH dependent quinone reductase (QOR), aldo-keto reductase (AKR), bifunctional aspartate kinase-homoserine reductase (AK-HSD) and mitochondrial import membrane translocase subunit (TIM9), or a fragment, homolog or variant thereof. The transgenic plant has increased tolerance to salt as compared to a corresponding non-transgenic plant.

Abstract: Catalytically treating groundwater (10), surface water, or above surface water, contaminated (12) with halogenated organic compounds being members of chlorotriazine, chloroacetanilide, or halogenated aliphatic, herbicide groups, and, halogen containing analogs and derivatives thereof. Method: exposing contaminated water to catalytic amount of electron transfer mediator (18) under reducing conditions, to decrease concentrations of halogenated organic compounds. System: at least one electron transfer mediator (18) contained in at least one (in-situ or/and ex-situ) unit (20), for exposing to contaminated water under reducing conditions. Exemplary electron transfer mediators are porphyrinogenic organometallic complexes, being metalloporphyrins, metallocorrins, or metallochlorins. Exemplary metalloporphyrins are a [TMPyP], [TP(OH)P], [TPP], or [TBSP], free base porphyrin complexed to a transition metal (cobalt, nickel, iron, zinc, or copper).

Abstract: Peptides corresponding partially to positions 55-64 of the sequence of the complement component peptide C3a are capable of preventing and treating mast cell- and basophil-mediated disorders by inhibiting IgE- or IgG-mediated triggering and/or by inhibiting the Fc?RI- and/or Fc?R-induced secretory response, while obviating the anaphylatoxic response. These peptides are useful for prevention and/or treatment of allergic disorders where mucosal-type and/or serosal-type mast cells and/or basophils are involved such as asthma, allergic dermatosis, and gastrointestinal allergies.

Abstract: Anti-inflammatory peptides derived from naturally occurring digests of proteins including apolipoprotein A-I, apolipoprotein A-II, fibrinogen ? chain, fibrinogen Aa, low-density lipoprotein receptor, ADAM 8, cadherin 4, and calcitonin receptor are provided, along with pharmaceutical compositions comprising same and methods of treating inflammatory diseases using same.

Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.

Abstract: The present invention is related to the field of compartmentalized libraries of genetic elements and the selection of biologically active molecules and the genes encoding same from said libraries. The selection assay of the invention utilizes water-in-oil emulsions and is particularly advantageous in applications in the field of directed-evolution, as exemplified herein for selection of protein inhibitors of DNA nucleases.

Abstract: Compositions comprising nucleic acids encoding the ? chain of IL-2 receptor (IL-2Ra, CD25), homologs and fragment thereof, are effective in the treatment and prevention of T cell mediated pathologies. Methods are provided for enhancing anti-ergotypic T cell activity in a subject in need thereof, and for treating or preventing T cell mediated pathologies, such as autoimmune disease, inflammatory diseases and graft rejection.

Abstract: The osmoprotectants proline, 2-methyl-4-carboxy-3,4,5,6-tetrahydropyrimidine (“THP(B)”, and 2-methyl-4-carboxy-5-hydroxy-3,4,5,6,-tetrahydropyrimidine (“THP(A)”) are capable of increasing the thermal stability of DNA polymerases at elevated temperatures. THP(B) is further effective in lowering the melting temperature of double-stranded DNA. Proline, THP(A) and THP(B) are thus useful in procedures involving melting of double-stranded DNA and/or polymerase-mediated DNA synthesis, such as in primer extension, in PCR (polymerase chain reaction) amplification and in DNA sequencing.

Abstract: Improvements in the selective extraction of relatively low molecular weight oils from coal, coal liquids, oil shales, shale oils, oil sands, heavy and semi-heavy oils, bitumens, and the like are provided by a continuous process involving contacting the material to be treated with supercritical water in a continuous operation at pressures of from 500 psi to 3000 psi, temperatures of 250° C. to 450° C., and in-reactor dwell times generally in excess of 25 seconds and up to 10 minutes.

Abstract: Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection.

Abstract: Post-translational O-sulfonation of a serine or threonine residue of proteins is detected, optionally comparatively, wherein the detected O-sulfonation is detected under a first physiological condition, and is compared with a control O-sulfonation detected under a second physiological condition, and a difference between the detected and control O-sulfonations indicates a difference between the first and second physiological conditions. Predetermined changes in physiological conditions are used to infer specific changes in O-sulfonation. Proteins are modified by introducing a predetermined change in O-sulfonation at a serine or threonine residue of the protein, and optionally, detecting a resultant change in O-sulfonation. These methods include introducing or increasing O-sulfonation, eliminating or reducing O-sulfonation; and derivatizing or substituting O-sulfonation.

Abstract: A peptide corresponding to positions 62-71 of the sequence of human C-reactive protein (CRP) of the formula: Glu62-Ile-Leu-Ile-Phe-Trp-Ser-Lys-Asp-Ile71 and modifications thereof obtained by substitution, deletion, or addition of amino acids, amidation of the C-terminal or acylation of the N-terminal, are capable of inhibiting in vitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG) and can be used for the treatment of chronic inflammation conditions such as rheumatoid arthritis, pulmonary emphysema, cystic fibrosis, bronchitis, asthma and some acute respiratory distress syndrome.

Abstract: The present invention provides molecular weight markers for accurate determination of the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight. The molecular weight markers also optimally demonstrate biological activity similar to glatiramer acetate or corresponding copolymers and can be used for treating or preventing various immune diseases. In addition, the subject invention provides pharmaceutical compositions for the treatment of immune diseases comprising a polypeptide having an identified molecular weight and an amino acid composition corresponding to glatiramer acetate or a terpolymer.

Abstract: Methods and kits for (i) determining a risk of a subject to develop cancer; (ii) evaluating an effectiveness and dosage of cancer therapy administered to a cancer patient; and (iii) determining a presence of correlation or non-correlation between an activity of at least one DNA repair enzyme and at least one cancer, are disclosed.

Abstract: The osmoprotectants proline, 2-methyl-4-carboxy-3,4,5,6-tetrahydropyrimidine (“THP(B)”, and 2-methyl-4-carboxy-5-hydroxy-3,4,5,6,-tetrahydropyrimidine (“THP(A)”) are capable of increasing the thermal stability of DNA polymerases at elevated temperatures. THP(B) is further effective in lowering the melting temperature of double-stranded DNA. Proline, THP(A) and THP(B) are thus useful in procedures involving melting of double-stranded DNA and/or polymerase-mediated DNA synthesis, such as in primer extension, in PCR (polymerase chain reaction) amplification and in DNA sequencing.

Abstract: A method for treating cancer comprising administering a 1,3,4,6-tetrahydroxy-helianthrone derivative. The compounds can be used in the absence of light irradiation or for photodynamic therapy of solid tumors wherein the tumor site is subjected to light irradiation after administration of the active ingredient. A preferred compound is 10,13-dimethyl-1,3,4,6-tetrahydroxy-helianthrone.

Abstract: A planar optical crossbar switch comprising two thin planar substrates, on each of which are recorded or attached two holographic lenses between which light propagates by means of total internal reflection. The first lens is a negative cylindrical lens, used to input the incident light signal to the substrate, and the second lens is a positive cylindrical lens. The two substrates are disposed at right angles to each other in such a way that the positive lenses are positioned one on top of the other with a spatial light modulator sandwiched between them or beneath them. A linear array of detectors collects the output signal from the negative lens on the second substrate.